PL3604510T3 - Antidota na inhibitory czynnika xa i sposoby ich stosowania - Google Patents

Antidota na inhibitory czynnika xa i sposoby ich stosowania

Info

Publication number
PL3604510T3
PL3604510T3 PL19179764.6T PL19179764T PL3604510T3 PL 3604510 T3 PL3604510 T3 PL 3604510T3 PL 19179764 T PL19179764 T PL 19179764T PL 3604510 T3 PL3604510 T3 PL 3604510T3
Authority
PL
Poland
Prior art keywords
antidotes
inhibitors
factor
methods
same
Prior art date
Application number
PL19179764.6T
Other languages
English (en)
Inventor
Uma Sinha
Genmin Lu
Pamela B Conley
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of PL3604510T3 publication Critical patent/PL3604510T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
PL19179764.6T 2009-03-30 2010-03-29 Antidota na inhibitory czynnika xa i sposoby ich stosowania PL3604510T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16488609P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
PL3604510T3 true PL3604510T3 (pl) 2025-07-28

Family

ID=42558585

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19179764.6T PL3604510T3 (pl) 2009-03-30 2010-03-29 Antidota na inhibitory czynnika xa i sposoby ich stosowania

Country Status (11)

Country Link
US (6) US8268783B2 (pl)
EP (3) EP3121271B1 (pl)
DK (1) DK3604510T3 (pl)
ES (2) ES2607935T3 (pl)
FI (1) FI3604510T3 (pl)
HU (1) HUE071850T2 (pl)
LT (1) LT3604510T (pl)
PL (1) PL3604510T3 (pl)
PT (2) PT3604510T (pl)
SI (1) SI3604510T1 (pl)
WO (1) WO2010117729A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
BRPI0816837B1 (pt) * 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
PT3604510T (pt) 2009-03-30 2025-06-24 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
EP2760887B1 (en) * 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
KR20140131957A (ko) 2012-02-14 2014-11-14 포톨라 파마슈티컬스, 인코포레이티드 Xa 인자 억제제에 대한 재조합 해독제를 제조하는 방법
PT2861614T (pt) 2012-06-14 2017-01-26 Portola Pharm Inc Método para a purificação de derivados do fator xa recombinantes
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
US10562192B2 (en) * 2013-08-29 2020-02-18 Ged Integrated Solutions, Inc. Window cleaning system and method
US9545383B2 (en) 2014-04-01 2017-01-17 Massachusetts Institute Of Technology Blood clotting control
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CA2961739C (en) * 2014-08-20 2024-04-30 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108883160B (zh) 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
CN110248964B (zh) 2017-02-01 2024-08-27 诺和诺德股份有限公司 促凝血抗体
FR3064917A1 (fr) * 2017-04-07 2018-10-12 Universite Grenoble Alpes Facteur x mute
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CA3083210A1 (en) * 2017-11-22 2018-11-20 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
JP7641903B2 (ja) 2019-02-07 2025-03-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド 頭蓋内出血の治療方法及び効果の評価方法
PT4010379T (pt) * 2019-08-08 2025-06-30 Alexion Pharma Inc Composições e métodos de preparação do fator xa e derivados
ES3020087T3 (en) 2020-09-21 2025-05-21 Instr Laboratory Co Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample
US12122817B2 (en) 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
WO2022236176A2 (en) * 2021-05-07 2022-11-10 City Of Hope Fxa protein for treating and/or preventing covid-19

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE228564T1 (de) 1991-09-13 2002-12-15 Chiron Corp Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AU681074B2 (en) * 1992-03-20 1997-08-21 Millennium Pharmaceuticals, Inc. Glycosylation-mediated inhibition of factor X
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
WO1998039456A1 (en) 1997-03-07 1998-09-11 Washington University Factor x variant
JPH1149800A (ja) 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
US20040198660A1 (en) 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
EP1723422A2 (en) 2004-03-05 2006-11-22 The Scripps Research Institute High throughput glycan microarrays
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
CN102336702B (zh) 2005-11-08 2015-02-11 米伦纽姆医药公司 Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
CN101578113B (zh) 2007-01-11 2015-04-22 诺和诺德公司 抗-kir抗体、制剂及其应用
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
US8455439B2 (en) * 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010070713A1 (ja) 2008-12-19 2010-06-24 富士通株式会社 情報処理装置、制御方法
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
PT3604510T (pt) * 2009-03-30 2025-06-24 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
CA2961739C (en) * 2014-08-20 2024-04-30 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
EP3078378B1 (en) * 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa

Also Published As

Publication number Publication date
ES2607935T3 (es) 2017-04-04
LT3604510T (lt) 2025-07-10
ES3032746T3 (en) 2025-07-24
EP2414517A1 (en) 2012-02-08
EP3121271A1 (en) 2017-01-25
EP3604510B1 (en) 2025-03-26
EP3121271B1 (en) 2019-07-24
WO2010117729A1 (en) 2010-10-14
US20130129693A1 (en) 2013-05-23
US10190111B2 (en) 2019-01-29
EP2414517B1 (en) 2016-09-21
US20190309279A1 (en) 2019-10-10
US20210340515A1 (en) 2021-11-04
US10954503B2 (en) 2021-03-23
US20100255000A1 (en) 2010-10-07
US9109046B2 (en) 2015-08-18
DK3604510T3 (da) 2025-06-30
US20170233711A1 (en) 2017-08-17
HUE071850T2 (hu) 2025-09-28
SI3604510T1 (sl) 2025-08-29
EP3604510A1 (en) 2020-02-05
FI3604510T3 (fi) 2025-06-26
US20160002617A1 (en) 2016-01-07
PT2414517T (pt) 2016-12-27
PT3604510T (pt) 2025-06-24
US8268783B2 (en) 2012-09-18
US9587233B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
HUS2000057I1 (hu) Az XA faktor inhibitorainak antidótumai és ezek felhasználási módszerei
PT3604510T (pt) Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
EP2606031A4 (en) AUTOTAXINE INHIBITORS AND APPLICATIONS THEREOF
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
ZA201305495B (en) Compounds and their use as bace inhibitors
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
ZA201202906B (en) Novel naphthyridine derivatives and the use thereof as kinase inhibitors
IL222176B (en) Radioprotector compounds and methods
IL230917A (en) 1dyrk inhibitors and their uses
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
SG10201500041XA (en) Superhydrophilic and water-capturing surfaces
ZA201206718B (en) Pde10 inhibitors and related compositions and methods
IL214333A0 (en) Carbamoylphosphonates as inhibitors and uses thereof
HK1186212A (en) Mir-33 inhibitors and uses thereof
GB0908609D0 (en) New use of isoQC inhibitors
GB201018597D0 (en) Inhibitors
GB201003936D0 (en) Novel inhibitors